department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Darzalex Faspro · pharmadog

pharmadog
drugs
Darzalex Faspro

drug

patient view →

(daratumumab + hyaluronidase (human recombinant))

Marketedupdated 2mo ago

by Janssen Biotech Inc

Approved

community read0 votes

all catalysts(16)

approval · 15

DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval

(daratumumab + hyaluronidase (human recombinant))

DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval

(daratumumab + hyaluronidase (human recombinant))

DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval

(daratumumab + hyaluronidase (human recombinant))

DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval

(daratumumab + hyaluronidase (human recombinant))

DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval

(daratumumab + hyaluronidase (human recombinant))

DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval

(daratumumab + hyaluronidase (human recombinant))

DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval

(daratumumab + hyaluronidase (human recombinant))

DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval

(daratumumab + hyaluronidase (human recombinant))

DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval

(daratumumab + hyaluronidase (human recombinant))

DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval

(daratumumab + hyaluronidase (human recombinant))

DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval

(daratumumab + hyaluronidase (human recombinant))

DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval

(daratumumab + hyaluronidase (human recombinant))

DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval

(daratumumab + hyaluronidase (human recombinant))

DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval

(daratumumab + hyaluronidase (human recombinant))

DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval

(daratumumab + hyaluronidase (human recombinant))

phase 2 initiation · 1

phase 2 initiation

National Cancer Institute US — (daratumumab + hyaluronidase (human recombinant)) (Phase II Trial Initiation)

(daratumumab + hyaluronidase (human recombinant))

view all 16 catalysts →

News(0)

no news has mentioned this drug yet

brand

Darzalex Faspro

generic

(daratumumab + hyaluronidase (human recombinant)-fihj)

indication

Multiple Myeloma (Kahler Disease)

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 8

drugdaratumumab31 co-mentions · 16 sources
drugdaratumumab + Gene Therapy31 co-mentions · 16 sources
drugDARZALEX FASPRO30 co-mentions · 15 sources
tagApproval30 co-mentions · 15 sources
companyJanssen Biotech Inc15 co-mentions · 15 sources
tagOncology2 co-mentions · 1 sources
tagMultiple Myeloma2 co-mentions · 1 sources
companyNational Cancer Institute US1 co-mentions · 1 sources

Trials studying (daratumumab + hyaluronidase (human recombinant))

phase1A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myelomanot yet recruitingn=258
EP1Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodiesrecruitingn=8
phase3A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myelomarecruitingn=486
phase1A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adultsrecruitingn=228
phase3To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myelomanot yet recruitingn=284